The biopharma industry is faced with high rates of clinical failure in innovative therapeutics, often due to a lack of high-confidence targets. Meanwhile, disease genetics data and data on how genetics impact gene/protein’s function are emerging in large scale and ready for translation. Furthermore, methodologies such as Mendelian Randomization are maturing, presenting promising paths for progress.

At D2M, we leverage Genome Wide Association Studies (GWAS) along with emerging multi-functional omics data, gaining insights into novel therapeutic targets. Furthermore, we employ systemic Mendelian Randomization mimicking traditional randomized controlled trials for causal biology learning.

Driven by the insights from genetics research, D2M is developing a broadened innovative immunotherapy for a variety of diseases including cancer, autoimmune disorders, and inflammation. We are committed to improving people’s health by addressing the root causes of disease.